BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
110.15
-1.00 (-0.90%)
Jun 5, 2025, 4:00 PM - Market closed
BioNTech SE Revenue
BioNTech SE had revenue of 182.80M EUR in the quarter ending March 31, 2025, a decrease of -2.56%. This brings the company's revenue in the last twelve months to 2.75B, up 0.61% year-over-year. In the year 2024, BioNTech SE had annual revenue of 2.75B, down -27.96%.
Revenue (ttm)
2.75B EUR
Revenue Growth
+0.61%
P/S Ratio
8.92
Revenue / Employee
405,538 EUR
Employees
6,772
Market Cap
26.48B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.75B | -1.07B | -27.96% |
| Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BNTX News
- 2 days ago - Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO - CNBC
- 3 days ago - Bristol Myers CEO explains why he's spending billions on BioNTech deal - Invezz
- 3 days ago - Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race - Market Watch
- 3 days ago - BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb - WSJ
- 3 days ago - Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership - Reuters
- 9 days ago - BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 16 days ago - BioNTech plans up to $1.33 billion investment in the United Kingdom - Reuters
- 4 weeks ago - BioNTech: mRNA Challenges Amid Regulatory Uncertainty (Rating Downgrade) - Seeking Alpha